Joint radionuclide therapy-immunotherapy approach effective in prostate cancer model
Researchers grow intestinal cells from human-induced pluripotent stem cells
8 February 2021Hospitalized health care workers do not have worse COVID-19 outcomes
8 February 2021Joint radionuclide therapy-immunotherapy approach effective in prostate cancer model
A combination of radionuclide therapy and immunotherapy has proven successful in slowing the progression of prostate cancer and increasing survival time, according to new research published in the February issue of The Journal of Nuclear Medicine. The results of the murine study indicate that radionuclide therapy promotes prostate cancer immunogenicity, provoking a cellular response that makes the tumors more receptive to immunotherapy.
